Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocitopenija, idiopatinė - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 ir 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig - moroktokogas alfa - hemofilija a - antihemoraginiai - kraujavimo gydymas ir profilaktika pacientams, sergantiems hemofilija a (įgimtu viii faktoriaus trūkumu). refacto af tinka naudoti suaugusiems ir vaikams visose amžiaus grupėse, įskaitant naujagimiams. refacto af nėra von-willebrand faktorius, ir todėl nėra nurodyta von-willebrand liga.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

eli lilly nederland b.v. - olanzapinas - schizophrenia; bipolar disorder - psicholeptikai - adultsolanzapine fluorouracilu ir folino šizofrenija. olanzapine yra veiksminga palaikant ir klinikinio pagerėjimo metu tęsti gydymą pacientams, kurie parodė, pradinė reakcija į gydymą. olanzapine fluorouracilu gydyti vidutinio sunkumo ar sunkius manijos epizodas. pacientams, kurių manijos epizodas reagavo į olanzapine gydymas, olanzapine yra nurodytas pasikartojimo prevencijos pacientams, sergantiems bipoliniu sutrikimu.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumabas - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antinavikiniai vaistai - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanibas - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - vargatef skiriamas kartu su docetakseliu suaugusiems pacientams, sergantiems lokaliai išplitusiu, metastazavusiu ar vietiškai nesmulkiųjų ląstelių plaučių vėžiu (nslpv) gydymo, naviko adenokarcinoma po pirmos eilės chemoterapijos.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - ceritinibas - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - zykadia yra skirtas gydyti suaugusiems pacientams su teigiamu anaplazinės limfomos kinazės (alk) teigiamas išplėstinė nesmulkialąsteliniu plaučių vėžiu (nslpv) anksčiau gydytų.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

roche registration gmbh - aletinibo hidrochloridas - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - alecensa kaip monotherapy yra nurodyta pirmos eilės gydymas suaugusiems pacientams, sergantiems anaplastic limfoma kinazės (Šarminio)-teigiama advanced nesmulkialąstelinio plaučių vėžio (nsclc). alecensa kaip monotherapy fluorouracilu ir folino suaugusių pacientų su alk‑teigiamas advanced nsclc anksčiau gydomi crizotinib.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

les laboratoires servier - stroncio ranelatas - osteoporozė, po menopauzės - narkotikai kaulų ligų gydymui - stiprios osteoporozės gydymas moterims po menopauzės, kuriems yra didelė lūžių rizika, siekiant sumažinti stuburo ir klubo kaulų lūžių riziką.. gydymas sunkus osteoporozės suaugusiųjų vyrų, padidėja kaulų lūžių rizika. sprendimą paskirti stroncio ranelate turėtų būti, įvertinus atskiro paciento bendrą riziką.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

les laboratoires servier - stroncio ranelatas - osteoporozė, po menopauzės - narkotikai kaulų ligų gydymui - stiprios osteoporozės gydymas moterims po menopauzės, kuriems yra didelė lūžių rizika, siekiant sumažinti stuburo ir klubo kaulų lūžių riziką.. gydymas sunkus osteoporozės suaugusiųjų vyrų, padidėja kaulų lūžių rizika. sprendimą paskirti stroncio ranelate turėtų būti, įvertinus atskiro paciento bendrą riziką.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antinavikiniai vaistai - inkstų ląstelių carcinomatorisel yra nurodyta pirmos eilės gydymas suaugę pacientai, sergantys progresavusia inkstų ląstelių karcinoma (rbt) kurie turi ne mažiau kaip trys iš šešių prognostinė rizikos veiksniai. mantijos ląstelių lymphomatorisel fluorouracilu ir folino suaugusių pacientų su atsinaujino ir / arba ugniai atsparios mantijos ląstelių limfoma (mcl).